Information Provided By: 
Fly News Breaks for June 6, 2018
JAZZ
Jun 6, 2018 | 06:55 EDT
After attending the SLEEP conference where Jazz Pharmaceuticals presented a number of clinical updates, JPMorgan analyst Jessica Fye says JZP-110 "continues to impress." The analyst came away comfortable with her $450M peak forecast for the product. She expects approval in December and launch in Q1 of 2019. Fye continues to see potential for "substantial further stock appreciation" for Jazz over time and keeps an Overweight rating on the shares with a $185 price target.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
